UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
By Order of the Board of Directors Sam Martin Chief Financial Officer and Secretary May 2, 2022 |
April 25, 2016
Hampton, NJ
May 2, 2022.
stock are entitled to one vote per share on each matter to be voted upon. As of the record date, we had 98,718,48446,754,348 outstanding shares of common stock.
to distribute, receive, count and tabulate proxies.
Even if you plan to attend our Annual Meeting, we recommend that you also submit your proxy as described above so that your vote will be counted if you later decide not to attend our Annual Meeting.
What is the difference between holding shares as a stockholder of record and as a beneficial owner?
Broker non-votes occur when nominees, such as banks
owner.
the beneficial owner.
Assuming that a quorum is present, the following votes will be required:
Meeting and entitled to vote on this Proposal 2. Accordingly, abstentions, if any, will have the same effect as a vote against this Proposal 2. Broker non-votes, if any, will have no effect on this Proposal 3.
Directors | | | Age | | | Year First Became Director | | | Current Public Boards | |
Karen L. Shoos (Chair of the Board) | | | 68 | | | 2001 | | | 1 | |
Anthony S. Marucci (Chief Executive Officer) | | | 60 | | | 2008 | | | 2 | |
Keith L. Brownlie | | | 69 | | | 2017 | | | 1 | |
Cheryl L. Cohen | | | 56 | | | Nominee | | | 3 | |
Herbert J. Conrad | | | 89 | | | 2008 | | | 1 | |
James J. Marino | | | 72 | | | 2017 | | | 2 | |
Garry A. Neil, M.D. | | | 68 | | | Nominee | | | 1 | |
Harry H. Penner, Jr. | | | 76 | | | 1997 | | | 1 | |
Directors | Age | Year First Became Director | |||||
---|---|---|---|---|---|---|---|
Larry Ellberger (Chairman of the Board) | 68 | 2003 | |||||
Anthony S. Marucci (Chief Executive Officer) | 54 | 2008 | |||||
Herbert J. Conrad | 83 | 2008 | |||||
George O. Elston | 51 | 2008 | |||||
Harry H. Penner, Jr. | 70 | 1997 | |||||
Karen L. Shoos | 62 | 2001 | |||||
Richard A. van den Broek | 50 | 2014 |
The following biographical descriptions set forth certain information with respect to the Director Nominees, based on information furnished to Celldex by each Director Nominee.
President and a member of the Board of Directors of Powderject PLC, a U.K. vaccine company. From 1995 to 1999, Mr. Ellberger1994, Ms. Shoos held several senior executive positions at W.R. Grace & Co.the American Red Cross, including Interim Chief Executive Officer, Chief Financial Officer andActing Senior Vice President, Strategic PlanningBiomedical Services (1993 – 1994) and Development. From 1975Secretary and General Counsel (1990 – 1993). Prior to 1995, Mr. Ellberger held numerous senior executive positions atthe American Cyanamid Company, serving the last four years as Vice President, Corporate Development. Mr. Ellberger currently serves on the Board of DirectorsRed Cross, Ms. Shoos was a lawyer in private practice. Ms. Shoos earned her B.A. from Yale University and is a member of the Audit and Nominating Committees of NeuroDerm, Ltd., a NASDAQ-listed Israeli biotech company. He is also a Director of The Jewish Children's Museum. Mr. Ellberger received a B.A. in Economicsher J.D. from Columbia College and a B.Sc. in Chemical Engineering from Columbia School of Engineering.
Case Western Reserve University.
of new biotechnologylife science companies since 2001. From 1993 to 2001, Mr. Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, Mr. Penner was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company'scompany’s Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chairman of BioCT (formerly Connecticut United for Research Excellence,Excellence), and as Chairman of the Connecticut Board of Governors of Higher Education and the Connecticut Technology Council. Mr. Penner is currently onChairman of the Board of DirectorsCaroGen Corporation. Mr. Penner is also Chairman of New Haven Pharmaceuticals,the Board of NeuroCyte Therapeutics, Inc. (of which he is Executive Chairman), Prevention Pharmaceuticals, Inc., and Affinimark Technologies,QCDx LLC, and a board member of OmaxHealth, Inc., all privately held companies of which he is a founder. In addition to having served on the board of directors of several public and privately held life science companies, Mr. Penner served on the Board of Directors and Audit Committee of Altus Pharmaceuticals, Inc. until October 2009. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University.
Attributes, Experience and Skills | | | Karen L. Shoos | | | Anthony S. Marucci | | | Keith L. Brownlie | | | Cheryl L. Cohen | | | Herbert J. Conrad | | | James J. Marino | | | Garry A. Neil, M.D. | | | Harry H. Penner, Jr. | | ||||||||||||||||||||||||
Industry Experience | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Executive/Leadership Experience | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Scientific Research/Drug Development Experience | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | * | | | | | | | | |
Business Strategy/Operations Experience | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Financial Experience | | | | | | | | | | | * | | | | | | * | | | | | | * | | | | | | | | | | | | * | | | | | | | | | | | | * | | |
Commercial Experience | | | | | | | | | | | | | | | | | | | | | | | * | | | | | | * | | | | | | | | | | | | | | | | | | | | |
Mergers & Acquisitions Experience | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
Public Company Board Experience | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
| | Board Size: Total Number of Directors & Nominees | | | | 8 (includes two nominees) | | | ||||||||||||
| | Gender: | | | | Male | | | | Female | | | | Non-Binary | | | | Gender Undisclosed | | |
| | Directors & Nominees | | | | 6 (includes one nominee) | | | | 2 (includes one nominee) | | | | — | | | | — | | |
| | Demographic Background: | | | | | | | | | | | | | | | | | | |
| | African American or Black | | | | — | | | | — | | | | — | | | | — | | |
| | Alaskan Native or Native American | | | | — | | | | — | | | | — | | | | — | | |
| | Asian | | | | — | | | | — | | | | — | | | | — | | |
| | Hispanic or Latinx | | | | — | | | | — | | | | — | | | | — | | |
| | Native Hawaiian or Pacific Islander | | | | — | | | | — | | | | — | | | | — | | |
| | White | | | | 6 (includes one nominee) | | | | 2 (includes one nominee) | | | | — | | | | — | | |
| | Two or More Races or Ethnicities | | | | — | | | | — | | | | — | | | | — | | |
| | LGBTQ+ | | | | — | | | | — | | | | — | | | | — | | |
| | Undisclosed | | | | — | | | | — | | | | — | | | | — | | |
Richard A. van den Broek has been a director of Celldex since December 2014. Mr. van den Broek has served as Managing Partner of HSMR Advisors, LLC, an investment fund focused ondiverse talent pipeline for the biotechnology industry since 2004. From 2000 through 2003, he servedby engaging in local communities to provide exposure to biotechnology to students.
Board of Directors
number of meetings of all committees of our Board of Directors on which the Director served (during the periods for which the director served on such committee or committees).served. Our annual meeting of stockholders is generally held to coincide with one of the Board'sBoard’s regularly scheduled meetings. We do not have a formal policy requiring members of the Board of Directors to attend our annual meetings, although our directors typically attend the annual meeting. Each of the then current directors attended the 20152021 Annual Meeting of Stockholders.
Director selection criteria
Our Nominating and Corporate Governance Committee and our Board value diversity and, as such, also consider diversity of gender, race, national origin, education, professional experience and differences in viewpoints and skills when selecting members of our Board, however we have no formal policy regarding diversity of our Board of Directors.
Independence also is an important selection criterion for nomination to our Board. Independent directors should be free of any relationship with us, our management, other directors or other parties that may impair, or appear to impair, the director'sdirector’s ability to make independent judgments. Independent directors must satisfy the criteria for independence established by NASDAQ. Currently all of our directors are independent except for our Chief Executive Officer, Mr. Marucci.
Stockholder nominations for directorships
Stockholders may propose
proposed nominee.
Risk Oversight
Upon the recommendation of our Nominating and Corporate Governance Committee, we
Stockholder Communications
Name of Individual | | | Age | | | Position and Office | | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Anthony S. Marucci | | | | | President, Chief Executive Officer and Director | | ||||||
| | | | | Executive Vice President and Chief Scientific Officer | | ||||||
Sarah Cavanaugh | | | 47 | | | Senior Vice President, Corporate Affairs and Administration | | |||||
Elizabeth Crowley | | | 50 | | | Senior Vice President and Chief Product Development Officer | | |||||
Margo Heath-Chiozzi, M.D. | | | 65 | | | Senior Vice President, Regulatory Affairs | | |||||
Freddy Jimenez | | | 53 | | | Senior Vice President and General Counsel | | |||||
Sam Martin | | | 51 | | | Senior Vice President, Chief Financial Officer and Secretary | ||||||
| ||||||||||||
| ||||||||||||
Ronald Pepin, Ph.D. | | | | | Senior Vice President and Chief Business Officer | | ||||||
Richard Wright, Ph.D. | | | | | Senior Vice President and Chief Commercial Officer | | ||||||
Diane C. Young, M.D. | | | 66 | | | Senior Vice President, Chief Medical Officer | |
Avery W. Catlin joined Celldex in January 2000. Mr. Catlin has more than 25 years of financial and business expertise in the biotechnology and medical device industries. Prior to joining Celldex, he served as Vice President, Operations and Finance, and Chief Financial Officer of Endogen, Inc., a public life science research products company, from 1996 to 1999. From 1992 to 1996, Mr. Catlin held various financial positions at Repligen Corporation, a public biopharmaceutical company, serving the last two years as Chief Financial Officer. Earlier in his career, Mr. Catlin held the position of Chief
Financial Officer at MediSense, Inc., a Massachusetts-based medical device company. Mr. Catlin currently serves on the Board of Directors of Corbus Pharmaceuticals Holdings Inc., a publicly-held biopharmaceuticals company, and is Chair of the Audit Committee. Mr. Catlin received his B.A. degree from the University of Virginia and his M.B.A. from Babson College and is a Certified Public Accountant.
Thomas Davis, M.D. became Executive Vice President and Chief Medical Officer of Celldex in July 2014. Dr. Davis served as Senior Vice President and Chief Medical Officer of Celldex from March 2008 to July 2014 and as Vice President of Clinical Development and Chief Medical Officer of Celldex from April 2006 to March 2008. Prior to Celldex, Mr. Davis served as Chief Medical Officer at GenVec from July 2005 to April 2006. Dr. Davis was also Senior Director of Clinical Science at Medarex. He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr. Ron Levy on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. degree in Biophysics from Johns Hopkins University, his M.S. degree in Physiology from Georgetown University and his M.D. from Georgetown University School of Medicine.
Tibor Keler, Ph.D. became Executive Vice President and Chief Scientific Officer of Celldex in July 2014. Since May 2003, Dr. Keler has held a number of positions with Celldex, including as a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
In 2021, our Named Executive Officers were Mr. Marucci, Dr. Keler, Mr. Jimenez, Mr. Martin and Dr. Young.
it is unlikely to meet the primary overall survival endpoint in patients with minimal residual disease, we decided to discontinue the ACT IV study and do not anticipate investing in further development of Rintega.goals. Our Compensation Committee approved annual bonus payments for our executive officers, which resulted in a payout of 95.8%114% to 97.8%124% of our executive officers' 2015the 2021 bonus target for Mr. Marucci, Dr. Keler, Mr. Jimenez, Mr. Martin and Dr. Young, depending on the position. Further, stock options granted to our executive officers in 20152021 have exercise prices equal to 100% of the fair value on the date of grant and vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter based on continued service. We believe that stock options structured in this manner encourage our executive officers to focus on increasing stockholder value and stock price appreciation over the long term and limit unnecessary risk taking behavior, while promoting retention.
company-wide DE&I training.
advisory services in connection with the amendment and restatement of our 2008 Stock Option and Incentive Plan, including an increase in the number of shares reserved for issuance under the Plan. RadfordAon reports directly to the Compensation Committee and provides guidance on trends in executive and non-employee director compensation, the development of specific executive compensation programs, the composition of the Company'sCompany’s compensation peer group and other matters as directed by the Compensation Committee. The Company also participated in various RadfordAon surveys in 2015, 2014 and 2013. During 2015, 2014 and 2013, the Company paid Radford approximately $35,300, $52,300 and $15,400, respectively, in consulting fees directly related to these services.2021. In 2015, 2014 and 2013, Radford2021, Aon did not provide any other services to Celldex.
The Compensation Committee has assessed the independence of Aon and concluded that no conflict of interests exists under applicable SEC rules.
of March 2015 was analyzedapproved by the Compensation Committee and used to inform our decisions affecting executive compensation based on 2015 performance consisted of the following companies:
| Aclaris Therapeutics | | | RAPT Therapeutics | | |
Applied Molecular Transport | | | Rubius Therapeutics | | ||
| Chimerix, Inc. | | | Seres Therapeutics, Inc. | | |
| Enanta Pharmaceuticals | | | Spero Therapeutics | | |
| Evelo Biosciences | | | SQZ Biotechnologies Company | | |
| Five Prime Therapeutics, Inc. | | | Summit Therapeutics | | |
| Gritstone Oncology | | | Sutro Biopharma | | |
| Inovio Pharmaceuticals | | | Syndax Pharmaceuticals, Inc. | ||
Mersana Therapeutics | | | Syros Pharmaceuticals | |||
Precision BioSciences | | TCR2 Therapeutics | | |||
| ||||||
| ||||||
This
designed to achieve these objectives. We determine the percentage mix of compensation structures that we think is appropriate for each of our executive officers. In general, the Compensation Committee believes that a substantial percentage of the compensation of our executive officers should be performance based. The Compensation Committee uses its judgment, and experience and the recommendations of the chief executive officerChief Executive Officer (except for his own compensation) to determine the appropriate mix of compensation for each individual.
executive officer.
stockholders.
Named Executive Officers:
| | | Annual Salary | | | | | | | | | | | | | | |||||||||
Name | | | As of December 31, 2021 | | | As of December 31, 2020 | | | Increase $ | | | Increase % | | ||||||||||||
Anthony S. Marucci | | | | $ | 680,908 | | | | | $ | 657,882 | | | | | $ | 23,026 | | | | | | 3.5% | | |
Tibor Keler, Ph.D. | | | | $ | 483,645 | | | | | $ | 467,645 | | | | | $ | 16,000 | | | | | | 3.4% | | |
Freddy Jimenez | | | | $ | 391,230 | | | | | $ | 378,000 | | | | | $ | 13,230 | | | | | | 3.5% | | |
Sam Martin | | | | $ | 412,820 | | | | | $ | 398,860 | | | | | $ | 13,960 | | | | | | 3.5% | | |
Diane C. Young, M.D. | | | | $ | 438,141 | | | | | $ | 423,325 | | | | | $ | 14,816 | | | | | | 3.5% | | |
2021. The Compensation Committee considered the 2021 performance and determined that based on the success the Company had in accomplishing the significant milestones detailed above we exceeded (120%) our 2021 corporate goals for pipeline development and business and financial operations. Our corporate goals for 20152021 and the level at which the Compensation Committee determined they were achieved are as follows:
| 2015 Corporate Goal | Relative Weight | 2015 Achievement | ||||||
---|---|---|---|---|---|---|---|---|---|
(1) | Late Stage Development Assets: | ||||||||
Rintega (Rindopepimut) Development Activities | 40 | 100 | % | ||||||
• Continue to execute the Phase 3 ACT IV pivotal registration study in accordance with applicable regulations, guidelines and plans | |||||||||
• Define and execute next clinical / regulatory steps for recurrent/ refractory GBM based on emerging results from the ReACT study | |||||||||
• Progess registration and marketing strategy in US and ROW, including key internal hires to support BLA submission and commercial launch | |||||||||
Glembatumumab Vedotin (CDX-011) Development Activities | 10 | 100 | % | ||||||
• Continue to accrued patients into the pivotal METRIC study in TNBC | |||||||||
• Initiate and continue patient accrual of the CDX-011 metastatic melanoma trial | |||||||||
• Support expanded development of CDX-011 through external collaborations (lung cancer, osteosarcoma, uveal melanoma) | |||||||||
• Progress registration and marketing strategy in US and ROW | |||||||||
Varlilumab (CDX-1127) Development Activities | 10 | 100 | % | ||||||
• Complete site activation and initial dose escalation for CDX-1127 Phase 1/2 combination studies | |||||||||
• Support expanded development through external collaborations | |||||||||
• Assess opportunities for potential registration pathways for CDX-1127 | |||||||||
• Identify CMOs and initiate external manufacturing activities to support EU and late stage development activities | |||||||||
(2) | Early Stage Development Assets: | 5 | 100 | % | |||||
CDX-1401 Development Activities | |||||||||
• Execute development activities of CDX-1401 through internal and external collaborations | |||||||||
• Assess market opportunities for CDX-1401 | |||||||||
CDX-301 Development Activities | |||||||||
• Complete site activation and progress patient enrollment of the pilot study of CDX-301 in HSCT +/– Mozobil | |||||||||
• Support expanded development of CDX-301 through external collaborations | |||||||||
CDX-014 or Other Product Candidate Development Activities | |||||||||
• Complete manufacturing and IND-enabling studies of CDX-014 to support IND filing | |||||||||
• Define 2nd generations and new product opportunities within research | |||||||||
(3) | Business and Financial Operations: | 35 | 91 | % | |||||
• Provide sufficient cash through either financings or partnerships and cost reductions to extend runway through 2017 | |||||||||
• Execute on the Company's BD strategy for internal and external collaborations; access to new technologies; complete a licensing transaction with respect to pipeline assets in 2015, if appropriate | |||||||||
• Build infrastructure to support expanding Product Development and Commercial organizations | |||||||||
| | | | | | | | | |
Totals: | 100 | 97 | % | ||||||
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
2021 Corporate Goals | | | Relative Weight | | | 2021 Achievement | | ||||||
Pipeline Development: | | | | | 50 | | | | | | 120% | | |
CDX-0159 | | | | | | | | | | | | | |
• Deliver final results from Phase 1b CIndU trial | | | | | | | | | | | | | |
• Deliver final results from Phase 1b CSU trial | | | | | ��� | | | | | | | | |
• Initiate Phase 1b prurigo nodularis (PN) trial | | | | | | | | | | | | | |
• Successfully manufacture and introduce sub-Q formulation into the clinic | | | | | | | | | | | | | |
• Prepare for initiation of Phase 2 in chronic urticaria | | | | | | | | | | | | | |
• Continue to evaluate CDX-0159 disease opportunities through internal efforts/external collaborations | | | | | | | | | | | | | |
CDX-1140 | | | | | | | | | | | | | |
• Deliver results in combination with pembro and from first stage of evaluation in combination with chemotherapy | | | | | | | | | | | | | |
• Define future development strategy | | | | | | | | | | | | | |
• Execute on Bridge grant commitments, including oversight of external clinical development and manufacture of CDX-301 | | | | | | | | | | | | | |
CDX-527 | | | | | | | | | | | | | |
• Complete enrollment in dose escalation portion of CDX-527 Phase 1 trial | | | | | | | | | | | | | |
• Initiate Phase 1 study | | | | | | | | | | | | | |
• Complete enrollment in initial dose expansion cohorts within CDX-527 Phase 1 trial | | | | | | | | | | | | | |
• Define future development strategy | | | | | | | | | | | | | |
Earlier stage pipeline assets | | | | | | | | | | | | | |
• Select follow on molecule (KIT bispecific) for development | | | | | | | | | | | | | |
• Continued evaluation and development of next R&D targets | | | | | | | | | | | | | |
Business and Financial Operations: | | | | | 50 | | | | | | 120% | | |
• Execute on D&I initiative focused on promoting inclusion and diversity broadly at Celldex and on exploring ways to ensure our industry has a robust and diverse talent pipeline | | | | | | | | | | | | | |
• Preserve two years of cash (through 2023) even if burn increases with clinical success | | | | | | | | | | | | | |
• Increase/maintain institutional ownership from 83% to 85% | | | | | | | | | | | | | |
• Obtain term sheet for significant in/out-licensing, collaboration or M&A transaction, as appropriate | | | | | | | | | | | | | |
• Provide sufficient cash to extend runway through 2024, as appropriate | | | | | | | | | | | | | |
Totals: | | | | | 100 | | | | | | 120% | | |
On April 11, 2015, the Compensation Committee of the Board of Directors approved the amendment and restatement of the 2008 Plan, subject to approval at the Annual Meeting by our stockholders, including an increase in the number of shares reserved for issuance thereunder by 6,950,000 to 14,350,000 shares. At the Annual Meeting of stockholders in June 2015, our stockholders approved such amendment and restatement of the 2008 Plan.
Officers.
plus (ii) 150% (200%, in the case of Mr. Marucci) of the highest one-year Annual Bonusannual bonus actually received by the Executiveexecutive during the preceding two full fiscal years prior to the date of termination. We use a "double trigger"“double trigger” with respect to benefits that are to be provided in connection with a change of control. A change of control does not itself trigger benefits; rather, benefits are paid only if the employment of the executive is terminated by us other than for cause, death or disability or by the executive for good reason during the one year period immediately following the change of control. We believe a "double trigger"“double trigger” benefit maximizes shareholder value because it prevents a windfall to executives in the event of a change of control in which the executive retains significant responsibility as defined in his or her individual agreement, while still providing our executives appropriate incentives to cooperate in negotiating any change of control that may put their jobs at risk.
Our
enhance the link between our long-term strategy and objectives and the incentives for our executive officers and enhancing alignment between our executive officers’ and our shareholders’ interests.
officers, other than the Chief Executive Officer and Chief Financial Officer, who were serving as executive officers as of December 31, 20152021 (collectively, the "Named“Named Executive Officers"Officers”).
Name and Principal Position | Years | Salary ($) | Bonus ($)(1) | Stock Awards ($) | Option Awards ($)(2) | Non-Equity Incentive Plan Compensation ($) | Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) | All Other Compensation ($)(3) | Total ($) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anthony S. Marucci | 2015 | 559,400 | 302,924 | — | 4,371,528 | — | — | 39,874 | 5,273,726 | |||||||||||||||||||
President and Chief | 2014 | 520,879 | 293,234 | — | 2,431,856 | — | — | 64,937 | 3,310,906 | |||||||||||||||||||
Executive Officer | 2013 | 496,388 | 375,000 | — | 2,940,280 | — | — | 15,120 | 3,826,788 | |||||||||||||||||||
Avery W. Catlin | 2015 | 339,457 | 130,000 | — | 1,436,359 | — | — | 6,024 | 1,911,840 | |||||||||||||||||||
Senior Vice President and | 2014 | 317,017 | 102,097 | — | 799,038 | — | — | 5,717 | 1,223,869 | |||||||||||||||||||
Chief Financial Officer | 2013 | 307,735 | 130,000 | — | 945,090 | — | — | 5,767 | 1,388,592 | |||||||||||||||||||
Thomas Davis, M.D. | 2015 | 434,421 | 165,000 | — | 1,818,868 | — | — | 9,297 | 2,427,586 | |||||||||||||||||||
Executive Vice President | 2014 | 407,453 | 148,960 | — | 1,011,826 | — | — | 8,749 | 1,576,988 | |||||||||||||||||||
and Chief Medical Officer | 2013 | 389,404 | 200,000 | — | 1,207,615 | — | — | 8,364 | 1,805,383 | |||||||||||||||||||
Tibor Keler., Ph.D. | 2015 | 409,996 | 159,000 | — | 1,818,868 | — | — | 3,800 | 2,391,664 | |||||||||||||||||||
Executive Vice President | 2014 | 384,517 | 158,500 | — | 1,011,826 | — | — | 3,763 | 1,558,606 | |||||||||||||||||||
and Chief Scientific Officer | 2013 | 367,484 | 186,000 | — | 1,207,615 | — | — | 3,651 | 1,764,750 | |||||||||||||||||||
Ronald Pepin, Ph.D. | 2015 | 338,078 | 97,000 | — | 1,436,359 | — | — | 6,761 | 1,878,198 | |||||||||||||||||||
Senior Vice President and | 2014 | 321,481 | 98,083 | — | 799,038 | — | — | 6,425 | 1,225,027 | |||||||||||||||||||
Chief Business Officer | 2013 | 311,654 | 100,000 | — | 945,090 | — | — | 6,474 | 1,363,218 |
Name and Principal Position | | | Years | | | Salary ($) | | | Bonus ($)(1) | | | Stock Awards ($) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($) | | | Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) | | | All Other Compensation ($)(3) | | | Total ($) | | |||||||||||||||||||||||||||
Anthony S. Marucci | | | | | 2021 | | | | | | 668,509 | | | | | | 490,254 | | | | | | — | | | | | | 4,868,797 | | | | | | — | | | | | | — | | | | | | 18,334 | | | | | | 6,045,894 | | |
President and Chief | | | | | 2020 | | | | | | 644,257 | | | | | | 395,000 | | | | | | — | | | | | | 1,950,788 | | | | | | — | | | | | | — | | | | | | 16,623 | | | | | | 3,006,668 | | |
Executive Officer | | | | | 2019 | | | | | | 619,478 | | | | | | 284,661 | | | | | | — | | | | | | 208,580 | | | | | | — | | | | | | — | | | | | | 15,601 | | | | | | 1,128,320 | | |
Tibor Keler., Ph.D. | | | | | 2021 | | | | | | 475,030 | | | | | | 265,000 | | | | | | — | | | | | | 1,977,949 | | | | | | — | | | | | | — | | | | | | 8,483 | | | | | | 2,726,462 | | |
Executive Vice President and | | | | | 2020 | | | | | | 457,405 | | | | | | 190,000 | | | | | | — | | | | | | 859,939 | | | | | | — | | | | | | — | | | | | | 7,508 | | | | | | 1,514,852 | | |
Chief Scientific Officer | | | | | 2019 | | | | | | 442,474 | | | | | | 135,549 | | | | | | — | | | | | | 125,148 | | | | | | — | | | | | | — | | | | | | 4,182 | | | | | | 707,353 | | |
Freddy Jimenez(4) | | | | | 2021 | | | | | | 382,208 | | | | | | 190,000 | | | | | | — | | | | | | 1,586,706 | | | | | | — | | | | | | — | | | | | | 7,490 | | | | | | 2,166,404 | | |
Senior Vice President and | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
General Counsel | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sam Martin | | | | | 2021 | | | | | | 405,303 | | | | | | 205,000 | | | | | | — | | | | | | 1,847,535 | | | | | | — | | | | | | — | | | | | | 9,044 | | | | | | 2,466,882 | | |
Senior Vice President and | | | | | 2020 | | | | | | 391,397 | | | | | | 142,000 | | | | | | — | | | | | | 840,829 | | | | | | — | | | | | | — | | | | | | 8,671 | | | | | | 1,382,897 | | |
Chief Financial Officer | | | | | 2019 | | | | | | 374,231 | | | | | | 103,000 | | | | | | — | | | | | | 89,689 | | | | | | — | | | | | | — | | | | | | 8,097 | | | | | | 575,017 | | |
Diane C. Young, M.D.(5) | | | | | 2021 | | | | | | 430,163 | | | | | | 200,000 | | | | | | — | | | | | | 1,564,970 | | | | | | — | | | | | | — | | | | | | 5,834 | | | | | | 2,200,967 | | |
Senior Vice President, | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Chief Medical Officer | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Estimated Future Payouts Under Equity Incentive Plan Awards | All Other Stock Awards: Number of Shares or Units (#) | | Grant Date Fair Value of Stock and Option Awards ($)(2) | ||||||||||||||||||||
| | Exercise or Base Price of Option Awards ($/Sh)(1) | |||||||||||||||||||||||
Name | Grant Date | Threshold (#) | Target (#) | Maximum (#) | |||||||||||||||||||||
Anthony S. Marucci | 6/10/15 | 280,000 | 25.41 | 4,371,528 | |||||||||||||||||||||
Avery W. Catlin | 6/10/15 | 92,000 | 25.41 | 1,436,359 | |||||||||||||||||||||
Thomas Davis, M.D. | 6/10/15 | 116,500 | 25.41 | 1,818,868 | |||||||||||||||||||||
Tibor Keler, Ph.D. | 6/10/15 | 116,500 | 25.41 | 1,818,868 | |||||||||||||||||||||
Ronald Pepin, Ph.D. | 6/10/15 | 92,000 | 25.41 | 1,436,359 |
| | | | | | | | | Estimated Future Payouts Under Equity Incentive Plan Awards | | | All Other Stock Awards: Number of Shares of Stock or Units (#) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise or Base Price of Option Awards ($/Sh)(1) | | | Grant Date Fair Value of Stock and Option Awards ($)(2) | | |||||||||||||||
Name | | | Grant Date | | | Threshold (#) | | | Target (#) | | | Maximum (#) | | ||||||||||||||||||||||||
Anthony S. Marucci | | | | | 6/17/21 | | | | | | | | | | | | | | | | | | 224,000 | | | | | | 28.00 | | | | | | 4,868,797 | | |
Tibor Keler, Ph.D. | | | | | 6/17/21 | | | | | | | | | | | | | | | | | | 91,000 | | | | | | 28.00 | | | | | | 1,977,949 | | |
Freddy Jimenez | | | | | 6/17/21 | | | | | | | | | | | | | | | | | | 73,000 | | | | | | 28.00 | | | | | | 1,586,706 | | |
Sam Martin | | | | | 6/17/21 | | | | | | | | | | | | | | | | | | 85,000 | | | | | | 28.00 | | | | | | 1,847,535 | | |
Diane Young, M.D. | | | | | 6/17/21 | | | | | | | | | | | | | | | | | | 72,000 | | | | | | 28.00 | | | | | | 1,564,970 | | |
| | | Option Awards | | | Stock Awards | | |||||||||||||||||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | ||||||||||||
Anthony S. Marucci(1) | | | | | — | | | | | | 224,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Anthony S. Marucci(1) | | | | | 91,875 | | | | | | 153,125 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Anthony S. Marucci(1) | | | | | 62,500 | | | | | | 37,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Anthony S. Marucci(1) | | | | | 62,706 | | | | | | 8,959 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Anthony S. Marucci | | | | | 31,665 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Anthony S. Marucci | | | | | 31,665 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Anthony S. Marucci | | | | | 18,666 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Anthony S. Marucci | | | | | 18,666 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Anthony S. Marucci | | | | | 18,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Anthony S. Marucci | | | | | 18,666 | | | | | | — | | | | | | | | | 85.35 | | | | | | 9/12/22 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.(1) | | | | | — | | | | | | 91,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
| Option Awards | Stock Awards | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#) | |||||||||||||||||||
Anthony S. Marucci(1) | — | 280,000 | 25.41 | 6/10/25 | ||||||||||||||||||||||||
Anthony S. Marucci(1) | 105,000 | 175,000 | 13.45 | 6/4/24 | ||||||||||||||||||||||||
Anthony S. Marucci(1) | 157,500 | 122,500 | 16.36 | 7/1/23 | ||||||||||||||||||||||||
Anthony S. Marucci(1) | 227,500 | 52,500 | 5.69 | 9/12/22 | ||||||||||||||||||||||||
Anthony S. Marucci | 180,400 | — | 2.80 | 8/5/21 | ||||||||||||||||||||||||
Anthony S. Marucci | 164,000 | — | 4.50 | 1/21/20 | ||||||||||||||||||||||||
Anthony S. Marucci | 129,000 | — | 8.52 | 1/6/19 | ||||||||||||||||||||||||
Anthony S. Marucci | 254,243 | — | 8.16 | 3/7/18 | ||||||||||||||||||||||||
Avery W. Catlin(1) | — | 92,000 | 25.41 | 6/10/25 | ||||||||||||||||||||||||
Avery W. Catlin(1) | 34,500 | 57,500 | 13.45 | 6/4/24 | ||||||||||||||||||||||||
Avery W. Catlin(1) | 50,625 | 39,375 | 16.36 | 7/1/23 | ||||||||||||||||||||||||
Avery W. Catlin(1) | 73,125 | 16,875 | 5.69 | 9/12/22 | ||||||||||||||||||||||||
Avery W. Catlin | 80,000 | — | 2.80 | 8/5/21 | ||||||||||||||||||||||||
Avery W. Catlin | 70,000 | — | 4.50 | 1/21/20 | ||||||||||||||||||||||||
Avery W. Catlin | 11,000 | — | 8.52 | 1/6/19 | ||||||||||||||||||||||||
Thomas Davis, M.D.(1) | — | 116,500 | 25.41 | 6/10/25 | ||||||||||||||||||||||||
Thomas Davis, M.D.(1) | 43,687 | 72,813 | 13.45 | 6/4/24 | ||||||||||||||||||||||||
Thomas Davis, M.D.(1) | 64,687 | 50,313 | 16.36 | 7/1/23 | ||||||||||||||||||||||||
Thomas Davis, M.D.(1) | 93,437 | 21,563 | 5.69 | 9/12/22 | ||||||||||||||||||||||||
Thomas Davis, M.D. | 104,500 | — | 2.80 | 8/5/21 | ||||||||||||||||||||||||
Thomas Davis, M.D. | 95,000 | — | 4.50 | 1/21/20 | ||||||||||||||||||||||||
Thomas Davis, M.D. | 76,400 | — | 8.52 | 1/6/19 | ||||||||||||||||||||||||
Thomas Davis, M.D. | 148,825 | — | 8.16 | 3/7/18 | ||||||||||||||||||||||||
Tibor Keler, Ph.D.(1) | — | 116,500 | 25.41 | 6/10/25 | ||||||||||||||||||||||||
Tibor Keler, Ph.D.(1) | 43,687 | 72,813 | 13.45 | 6/4/24 | ||||||||||||||||||||||||
Tibor Keler, Ph.D.(1) | 64,687 | 50,313 | 16.36 | 7/1/23 | ||||||||||||||||||||||||
Tibor Keler, Ph.D.(1) | 93,437 | 21,563 | 5.69 | 9/12/22 | ||||||||||||||||||||||||
Tibor Keler, Ph.D. | 99,000 | — | 2.80 | 8/5/21 | ||||||||||||||||||||||||
Tibor Keler, Ph.D. | 90,000 | — | 4.50 | 1/21/20 | ||||||||||||||||||||||||
Tibor Keler, Ph.D. | 72,250 | — | 8.52 | 1/6/19 | ||||||||||||||||||||||||
Tibor Keler, Ph.D. | 254,243 | — | 8.16 | 3/7/18 | ||||||||||||||||||||||||
Ronald Pepin, Ph.D.(1) | — | 92,000 | 25.41 | 6/10/25 | ||||||||||||||||||||||||
Ronald Pepin, Ph.D.(1) | 34,500 | 57,500 | 13.45 | 6/4/24 | ||||||||||||||||||||||||
Ronald Pepin, Ph.D.(1) | 50,625 | 39,375 | 16.36 | 7/1/23 | ||||||||||||||||||||||||
Ronald Pepin, Ph.D.(1) | 73,125 | 16,875 | 5.69 | 9/12/22 | ||||||||||||||||||||||||
Ronald Pepin, Ph.D. | 100,000 | — | 3.52 | 7/1/21 |
| | | Option Awards | | | Stock Awards | | |||||||||||||||||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | ||||||||||||
Tibor Keler, Ph.D.(1) | | | | | 40,500 | | | | | | 67,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.(1) | | | | | 37,500 | | | | | | 22,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D.(1) | | | | | 22,749 | | | | | | 3,250 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D. | | | | | 10,799 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D. | | | | | 10,799 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D. | | | | | 7,766 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D. | | | | | 7,766 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D. | | | | | 7,666 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Tibor Keler, Ph.D. | | | | | 7,666 | | | | | | — | | | | | | | | | 85.35 | | | | | | 9/12/22 | | | | | | | | | | | | | | |
Freddy Jimenez(1) | | | | | — | | | | | | 73,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Freddy Jimenez(1) | | | | | 13,500 | | | | | | 22,500 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Freddy Jimenez(1) | | | | | 12,500 | | | | | | 7,500 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Freddy Jimenez(1) | | | | | 3,645 | | | | | | 521 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Freddy Jimenez | | | | | 1,666 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Freddy Jimenez | | | | | 266 | | | | | | — | | | | | | | | | 65.40 | | | | | | 8/11/26 | | | | | | | | | | | | | | |
Freddy Jimenez | | | | | 733 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Freddy Jimenez | | | | | 1,400 | | | | | | — | | | | | | | | | 112.50 | | | | | | 3/1/26 | | | | | | | | | | | | | | |
Sam Martin(1) | | | | | — | | | | | | 85,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Sam Martin(1) | | | | | 39,600 | | | | | | 66,000 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Sam Martin(1) | | | | | 8,296 | | | | | | 16,125 | | | | | | | | | 2.78 | | | | | | 6/19/29 | | | | | | | | | | | | | | |
Sam Martin(1) | | | | | 6,238 | | | | | | 3,292 | | | | | | | | | 9.02 | | | | | | 6/13/28 | | | | | | | | | | | | | | |
Sam Martin | | | | | 4,332 | | | | | | — | | | | | | | | | 34.80 | | | | | | 6/15/27 | | | | | | | | | | | | | | |
Sam Martin | | | | | 1,399 | | | | | | — | | | | | | | | | 70.80 | | | | | | 6/8/26 | | | | | | | | | | | | | | |
Sam Martin | | | | | 1,399 | | | | | | — | | | | | | | | | 381.15 | | | | | | 6/10/25 | | | | | | | | | | | | | | |
Sam Martin | | | | | 799 | | | | | | — | | | | | | | | | 201.75 | | | | | | 6/4/24 | | | | | | | | | | | | | | |
Sam Martin | | | | | 500 | | | | | | — | | | | | | | | | 245.40 | | | | | | 7/1/23 | | | | | | | | | | | | | | |
Sam Martin | | | | | 350 | | | | | | — | | | | | | | | | 95.55 | | | | | | 9/20/22 | | | | | | | | | | | | | | |
Diane Young, M.D(1) | | | | | — | | | | | | 72,000 | | | | | | | | | 28.00 | | | | | | 6/17/31 | | | | | | | | | | | | | | |
Diane Young, M.D(1) | | | | | 22,400 | | | | | | 45,000 | | | | | | | | | 10.38 | | | | | | 6/18/30 | | | | | | | | | | | | | | |
Diane Young, M.D(1) | | | | | 33,750 | | | | | | 26,250 | | | | | | | | | 2.71 | | | | | | 7/8/29 | | | | | | | | | | | | | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||
Name | | | Number of Shares Acquired on Exercise (#) | | | Value Realized on Exercise ($)(1) | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($) | | ||||||||||||
Anthony S. Marucci | | | | | 3,537 | | | | | | 20,161 | | | | | | — | | | | | | — | | |
Tibor Keler, Ph.D. | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Freddy Jimenez | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Sam Martin | | | | | 35,381 | | | | | | 1,386,246 | | | | | | — | | | | | | — | | |
Diane Young, M.D. | | | | | 4,600 | | | | | | 149,781 | | | | | | — | | | | | | — | | |
| Option Awards | Stock Awards | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Name | Number of Shares Acquired on Exercise (#) | Value Realized on Exercise ($) | Number of Shares Acquired on Vesting (#) | Value Realized on Vesting ($) | |||||||||
Anthony S. Marucci | — | — | — | — | |||||||||
Avery W. Catlin | 60,000 | $ | 754,000 | (1) | — | — | |||||||
Thomas Davis, M.D. | — | — | — | — | |||||||||
Tibor Keler, Ph.D. | — | — | — | — | |||||||||
Ronald Pepin, Ph.D. | — | — | — | — |
Executive benefits and payments upon termination | | | Voluntary resignation for no good reason | | | Voluntary resignation for good reason(1) | | | Termination by Celldex without cause(1) | | | Termination by Celldex for cause | | | Voluntary termination by the executive for good reason or termination by Celldex without cause in connection with or following change of control(2) | | |||||||||||||||
Anthony S. Marucci | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary | | | | $ | — | | | | | $ | 1,361,816 | | | | | $ | 1,361,816 | | | | | $ | — | | | | | $ | 1,361,816 | | |
Bonus | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 980,508 | | |
Equity Awards Acceleration(3) | | | | | — | | | | | | 2,080,205 | | | | | | 2,080,205 | | | | | | — | | | | | | 8,320,820 | | |
Continuation of Health Benefits | | | | | — | | | | | | 40,176 | | | | | | 40,176 | | | | | | — | | | | | | 40,176 | | |
Total | | | | $ | — | | | | | $ | 3,482,197 | | | | | $ | 3,482,197 | | | | | $ | — | | | | | $ | 10,703,320 | | |
Tibor Keler, Ph.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary | | | | $ | — | | | | | $ | 483,645 | | | | | $ | 483,645 | | | | | $ | — | | | | | $ | 967,290 | | |
Bonus | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 397,500 | | |
Equity Awards Acceleration(3) | | | | | — | | | | | | 944,730 | | | | | | 944,730 | | | | | | — | | | | | | 3,778,916 | | |
Continuation of Health Benefits | | | | | — | | | | | | 29,646 | | | | | | 29,646 | | | | | | — | | | | | | 29,646 | | |
Total | | | | $ | — | | | | | $ | 1,458,021 | | | | | $ | 1,458,021 | | | | | $ | — | | | | | $ | 5,173,352 | | |
Freddy Jimenez | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary | | | | $ | — | | | | | $ | 391,230 | | | | | $ | 391,230 | | | | | $ | — | | | | | $ | 782,460 | | |
Bonus | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 285,000 | | |
Equity Awards Acceleration(3) | | | | | — | | | | | | 424,240 | | | | | | 424,240 | | | | | | — | | | | | | 1,696,954 | | |
Continuation of Health Benefits | | | | | — | | | | | | 40,176 | | | | | | 40,176 | | | | | | — | | | | | | 40,176 | | |
Total | | | | $ | — | | | | | $ | 855,646 | | | | | $ | 855,646 | | | | | $ | — | | | | | $ | 2,804,590 | | |
Sam Martin | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary | | | | $ | — | | | | | $ | 412,820 | | | | | $ | 412,820 | | | | | $ | — | | | | | $ | 825,640 | | |
Bonus | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 307,500 | | |
Equity Awards Acceleration(3) | | | | | — | | | | | | 861,331 | | | | | | 861,331 | | | | | | — | | | | | | 3,445,324 | | |
Continuation of Health Benefits | | | | | — | | | | | | 40,176 | | | | | | 40,176 | | | | | | — | | | | | | 40,176 | | |
Total | | | | $ | — | | | | | $ | 1,314,327 | | | | | $ | 1,314,327 | | | | | $ | — | | | | | $ | 4,618,640 | | |
Executive benefits and payments upon termination | Voluntary resignation for no good reason | Voluntary resignation for good reason(1) | Termination by Celldex not for cause(1) | Termination by Celldex for cause | Voluntary termination by the executive for good reason or termination by Celldex without cause in connection with or following change of control(2) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anthony S. Marucci | ||||||||||||||||
Base salary | $ | — | $ | 1,135,614 | $ | 1,135,614 | $ | — | $ | 1,135,614 | ||||||
Bonus | — | — | — | — | 605,848 | |||||||||||
Equity Awards Acceleration(3) | — | 228,681 | 228,681 | — | 914,725 | |||||||||||
Continuation of Health Benefits | — | 46,351 | 46,351 | — | 46,351 | |||||||||||
| | | | | | | | | | | | | | | | |
Total | $ | — | $ | 1,410,646 | $ | 1,410,646 | $ | — | $ | 2,702,538 | ||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Avery W. Catlin | ||||||||||||||||
Base salary | $ | — | $ | 332,440 | $ | 332,440 | $ | — | $ | 664,880 | ||||||
Bonus | — | — | — | — | 195,000 | |||||||||||
Equity Awards Acceleration(3) | — | 74,202 | 74,202 | — | 296,806 | |||||||||||
Continuation of Health Benefits | — | 34,195 | 34,195 | — | 34,195 | |||||||||||
| | | | | | | | | | | | | | | | |
Total | $ | — | $ | 440,837 | $ | 440,837 | $ | — | $ | 1,190,881 | ||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Thomas Davis, M.D. | ||||||||||||||||
Base salary | $ | — | $ | 433,885 | $ | 433,885 | $ | — | $ | 867,770 | ||||||
Bonus | — | — | — | — | 247,500 | |||||||||||
Equity Awards Acceleration(3) | — | 94,447 | 94,447 | — | 377,787 | |||||||||||
Continuation of Health Benefits | — | 46,351 | 46,351 | — | 46,351 | |||||||||||
| | | | | | | | | | | | | | | | |
Total | $ | — | $ | 574,683 | $ | 574,683 | $ | — | $ | 1,539,408 | ||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Executive benefits and payments upon termination | Voluntary resignation for no good reason | Voluntary resignation for good reason(1) | Termination by Celldex not for cause(1) | Termination by Celldex for cause | Voluntary termination by the executive for good reason or termination by Celldex without cause in connection with or following change of control(2) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tibor Keler, Ph.D. | ||||||||||||||||
Base salary | $ | — | $ | 409,523 | $ | 409,523 | $ | — | $ | 819,046 | ||||||
Bonus | — | — | — | — | 238,500 | |||||||||||
Equity Awards Acceleration(3) | — | 94,447 | 94,447 | — | 377,787 | |||||||||||
Continuation of Health Benefits | — | 46,351 | 46,351 | — | 46,351 | |||||||||||
| | | | | | | | | | | | | | | | |
Total | $ | — | $ | 550,321 | $ | 550,321 | $ | — | $ | 1,481,684 | ||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Ronald Pepin, Ph.D. | ||||||||||||||||
Base salary | $ | — | $ | 337,444 | $ | 337,444 | $ | — | $ | 674,888 | ||||||
Bonus | — | — | — | — | 145,500 | |||||||||||
Equity Awards Acceleration(3) | — | 74,202 | 74,202 | — | 296,806 | |||||||||||
Continuation of Health Benefits | — | 46,351 | 46,351 | — | 46,351 | |||||||||||
| | | | | | | | | | | | | | | | |
Total | $ | — | $ | 457,997 | $ | 457,997 | $ | — | $ | 1,163,545 | ||||||
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
Executive benefits and payments upon termination | | | Voluntary resignation for no good reason | | | Voluntary resignation for good reason(1) | | | Termination by Celldex without cause(1) | | | Termination by Celldex for cause | | | Voluntary termination by the executive for good reason or termination by Celldex without cause in connection with or following change of control(2) | | |||||||||||||||
Diane Young, M.D. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Base Salary | | | | $ | — | | | | | $ | 438,141 | | | | | $ | 438,141 | | | | | $ | — | | | | | $ | 876,282 | | |
Bonus | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 300,000 | | |
Equity Awards Acceleration(3) | | | | | — | | | | | | 745,236 | | | | | | 745,236 | | | | | | — | | | | | | 2,980,943 | | |
Continuation of Health Benefits | | | | | — | | | | | | 13,410 | | | | | | 13,410 | | | | | | — | | | | | | 13,410 | | |
Total | | | | $ | — | | | | | $ | 1,196,787 | | | | | $ | 1,196,787 | | | | | $ | — | | | | | $ | 4,170,635 | | |
|
Level | | | Minimum Required Level of Stock Ownership | |
CEO | | | 3 times annual base salary | |
Other Executive Officers | | | 1 times annual base salary | |
New board members
annual grant of 6,500 shares of restricted stock each year and (ii)received an annual stock option grant to purchase 10,30012,000 shares of the Company'sCompany’s common stock following the annual stockholders' meeting.
As2021 Annual Meeting of December 31, 2015, our non-employee directors had the following stock options outstanding: Larry Ellberger—26,300, Herbert J. Conrad—44,179, George O. Elston—44,179, Harry H. Penner, Jr.—26,300, Karen L. Shoos—26,300 and Richard van den Broek—18,300.
Stockholders.
Name | Fees Earned or Paid in Cash ($) | Stock Awards ($)(1) | Option Awards ($)(2) | Non-Equity Incentive Plan Compensation ($) | Change in Pension Value and Nonqualified Deferred Compensation Earnings | All Other Compensation ($) | Total ($) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Larry Ellberger | 110,000 | 165,165 | 160,810 | — | — | — | 435,975 | |||||||||||||||
Herbert J. Conrad | 80,000 | 165,165 | 160,810 | — | — | — | 405,975 | |||||||||||||||
George O. Elston | 100,000 | 165,165 | 160,810 | — | — | — | 425,975 | |||||||||||||||
Harry H. Penner, Jr. | 90,000 | 165,165 | 160,810 | — | — | — | 415,975 | |||||||||||||||
Karen L. Shoos | 100,000 | 165,165 | 160,810 | — | — | — | 425,975 | |||||||||||||||
Richard A. van den Broek | 90,000 | 165,165 | 160,810 | — | — | — | 415,975 |
Name | | | Fees Earned or Paid in Cash ($) | | | Stock Awards ($) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($) | | | Change in Pension Value and Nonqualified Deferred Compensation Earnings | | | All Other Compensation ($) | | | Total ($) | | |||||||||||||||||||||
Karen L. Shoos | | | | | 74,000 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 334,828 | | |
Keith L. Brownlie | | | | | 59,000 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 319,828 | | |
Herbert J. Conrad | | | | | 54,250 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 315,078 | | |
James J. Marino | | | | | 60,000 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 320,828 | | |
Harry H. Penner, Jr. | | | | | 53,750 | | | | | | — | | | | | | 260,828 | | | | | | — | | | | | | — | | | | | | — | | | | | | 314,578 | | |
The percentage of the common stock beneficially owned by each person or entity named in the following table is based on 98,718,48446,754,348 shares of common stock outstanding as of April 13, 20166, 2022 plus any shares issuable upon exercise of Presently Exercisable Options held by such person or entity.
Name and Business Address of Beneficial Owners* | | | Amount and Nature of Beneficial Ownership(1) | | | Percentage of Common Stock(2) | | ||||||
5% Holders | | | | | | | | | | | | | |
FMR LLC | | | | | 6,999,580(3) | | | | | | 15.0% | | |
245 Summer Street Boston, Massachusetts 02210 | | | | | | | | | | | | | |
RTW Investments, LP | | | | | 3,921,579(4) | | | | | | 8.4% | | |
40 10th Avenue 7th Floor New York, NY 10014 | | | | | | | | | | | | | |
BlackRock Inc. | | | | | 3,101,030(5) | | | | | | 6.6% | | |
55 East 52nd Street New York, NY 10055 | | | | | | | | | | | | | |
The Vanguard Group | | | | | 2,413,056(6) | | | | | | 5.2% | | |
100 Vanguard Blvd. Malvern, PA 19355 | | | | | | | | | | | | | |
State Street Corp | | | | | 2,368,040(7) | | | | | | 5.1% | | |
One Lincoln Street Boston, MA 02111 | | | | | | | | | | | | | |
Director Nominees and Named Executive Officers | | | | | | | | | | | | | |
Keith L. Brownlie | | | | | 22,165(8) | | | | | | ** | | |
Cheryl L. Cohen | | | | | — | | | | | | ** | | |
Herbert J. Conrad | | | | | 25,481(9) | | | | | | ** | | |
Freddy Jimenez | | | | | 37,900(10) | | | | | | ** | | |
Tibor Keler, Ph.D. | | | | | 172,693(11) | | | | | | ** | | |
James J. Marino | | | | | 34,203(12) | | | | | | ** | | |
Sam Martin | | | | | 98,224(13) | | | | | | ** | | |
Anthony S. Marucci | | | | | 408,511(14) | | | | | | ** | | |
Garry A. Neil, M.D. | | | | | — | | | | | | ** | | |
Harry H. Penner, Jr. | | | | | 25,708(15) | | | | | | ** | | |
Karen L. Shoos | | | | | 25,703(16) | | | | | | ** | | |
Diane C. Young, M.D. | | | | | 70,265(17) | | | | | | ** | | |
All Director Nominees and Executive Officers as a group (17 persons) | | | | | 1,303,981(18) | | | | | | 2.7% | | |
Name and Business Address of Beneficial Owners* | Amount and Nature of Beneficial Ownership(1) | Percentage of Common Stock(2) | |||||
---|---|---|---|---|---|---|---|
5% Holders | |||||||
FMR LLC | 14,796,853 | (3) | 15.0 | % | |||
Franklin Resources, Inc. | 9,804,892 | (4) | 9.9 | % | |||
OppenheimerFunds Inc. | 8,901,692 | (5) | 9.0 | % | |||
State Street Corporation | 8,561,225 | (6) | 8.7 | % | |||
First Trust Portfolios L.P. | 7,424,420 | (7) | 7.5 | % | |||
The Vanguard Group | 6,791,275 | (8) | 6.9 | % | |||
BlackRock, Inc. | 6,547,643 | (9) | 6.6 | % | |||
Directors and Executive Officers | |||||||
Avery W. Catlin | 411,988 | (10) | ** | ||||
Herbert J. Conrad | 62,679 | (11) | ** | ||||
Thomas Davis, M.D. | 707,341 | (12) | ** | ||||
Larry Ellberger | 79,800 | (13) | ** | ||||
George O. Elston | 62,679 | (14) | ** | ||||
Tibor Keler, Ph.D. | 805,609 | (15) | ** | ||||
Anthony S. Marucci | 1,443,075 | (16) | 1.4 | % | |||
Harry H. Penner, Jr. | 48,216 | (17) | ** | ||||
Ronald Pepin, Ph.D. | 315,249 | (18) | ** | ||||
Karen L. Shoos | 48,133 | (19) | ** | ||||
Richard A. van den Broek | 241,800 | (20) | ** | ||||
Richard Wright, Ph.D | 60,625 | (21) | ** | ||||
All Directors and Executive Officers as a group (11 persons) | 4,287,194 | (22) | 4.2 | % |
vote over 8,901,692 and the sole power to dispose or to direct the disposition of 8,901,692 shares.
Plan Category | | | (a) Number of securities to be issued upon exercise of outstanding options and rights(1) | | | (b) Weighted-average exercise price of outstanding options and rights | | | (c) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | | |||||||||
Equity compensation plans approved by security holders(2) | | | | | 4,077,667(3) | | | | | $ | 30.02 | | | | | | 3,492,692(4) | | |
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires Celldex's directors and executive, officers, and persons who are beneficial owners of more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission (the "SEC"). These persons are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. To our knowledge, based solely on a review of the copies of such reports furnished to us, and written representations that no other reports were required during the fiscal year ended December 31, 2015, all reports required to be filed2021, of which 3,304,217 shares are available for grants in the form of restricted stock, deferred stock, performance shares or unrestricted stock under Section 16(a) were filed on a timely basis.
the 2021 Omnibus Equity Incentive Plan.
Fee Category | | | 2021 | | | 2020 | | ||||||
| | | (In thousands) | | |||||||||
Audit Fees | | | | $ | 653 | | | | | $ | 745 | | |
Audit-Related Fees | | | | | — | | | | | | — | | |
Tax Fees | | | | | — | | | | | | — | | |
All Other Fees | | | | | 3 | | | | | | 3 | | |
Total Fees | | | | $ | 656 | | | | | $ | 748 | | |
Fee Category | 2015 | 2014 | |||||
---|---|---|---|---|---|---|---|
| (In thousands) | ||||||
Audit Fees | $ | 603 | $ | 517 | |||
Audit-Related Fees | 5 | — | |||||
Tax Fees | 254 | 43 | |||||
All Other Fees | 11 | 177 | |||||
| | | | | | | |
Total Fees | $ | 873 | $ | 737 | |||
| | | | | | | |
| | | | | | | |
| | | | | | | |
Audit Fees
Audit-Related Fees
Audit-related fees are for assurance and other activities not explicitly related to the audit of our financial statements.
Tax Fees
Tax fees are associated with tax compliance and tax planning related activities.
The Audit Committee is responsible for appointing, setting compensation and overseeing the work of the independent auditors. The Audit Committee has established a policy regarding pre-approval of all auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section 10A(g) of the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board) to be provided to Celldex by the independent auditor. However, the pre-approval requirement may be waived with respect to the provision of non-audit services for Celldex if the "de minimus"“de minimis” provisions of Section 10A(i)(1)(B) of the Exchange Act are satisfied.
"RESOLVED,
”
Stockholder approval of this Proposal No. 3 will require the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting.
Copies
Our audited financial statements for the fiscal year ended December 31, 2015 and certain other related financial and business information are contained in our 2015 Annual Report to Stockholders, which is being made available to our stockholders along with this proxy statement, but which is not deemed a part of the proxy soliciting material.
Secretary |
Hampton, NJApril 25, 2016
VOTE BY INTERNET - www.proxyvote.com Use
0000563185_1 R1.0.0.24
0000563185_2 R1.0.0.24